Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
RESEARCH TOOLSreports
Holding CGTX?
Track your performance easily
CGTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.34 - $2.95
Previous Close$0.63
Volume7.80M
Average Volume (3M)6.68M
Market Cap
$26.34M
Enterprise Value$4.91M
Total Cash (Recent Filing)$22.01M
Total Debt (Recent Filing)$580.00K
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Mar 26, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,547,995
10 Day Avg. Volume33,032,236
30 Day Avg. Volume6,684,610
Standard Deviation0.26
R-Squared0.05
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$5.50Price Target Upside772.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cognition Therapeutics News
PremiumCompany Announcements
Cognition Therapeutics Reports Promising Q3 2024 ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsCognition Therapeutics, Inc. reported dramatically improved efficacy in low p-Tau217 analysis, indicating significant cognitive and functional improvements in patients.
Drug DevelopmentThe SHINE study results highlight CT1812's potential effectiveness in early-stage Alzheimer's disease, showing more pronounced effects in these patients.
Financial OutlookPositive results from the SHIMMER trial could resurrect investor interest in CT1812 and Cognition overall; this may constitute a substantial value inflection point.
Bears Say
Clinical Trial ResultsPatients with p-tau217 above median levels showed similar changes from baseline compared to placebo, with CT1812 treatment being slightly worse than placebo.
Financial PerformanceThe company recorded a net loss of $0.25 per share, substantively wider than our forecast of a net loss of only $0.16 per share; this was mainly driven by higher-than-anticipated R&D spending.
Regulatory And Commercial RisksRisks include negative clinical data readouts, inability to advance CT1812 into pivotal trials in a timely manner, failure to generate favorable top-line data from pivotal trials, inability to secure regulatory approval of CT1812, poorer-than-expected commercial performance, possible partnership risks, and medium-term dilution risk.
---
Ownership Overview
30.54% Insiders
3.73% Mutual Funds
3.81% Other Institutional Investors
58.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.34 and its highest was $2.95 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Currently, no data Available
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 95 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.053.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 41,547,997 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at N/A.
---
Cognition Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (772.88% Upside)
$5.50 (772.88% Upside)
Blogger Sentiment
Bearish
CGTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 140.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 33.1%
Last 30 Days ▲ 43.5%
Last 30 Days ▲ 43.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.27%
12-Months-Change
Fundamentals
Return on Equity
-157.90%
Trailing 12-Months
Asset Growth
-28.87%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
---
CGTX Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a cautiously optimistic outlook for Cognition Therapeutics. The SHINE trial results, while not statistically significant, show promising trends in slowing cognitive decline, which are encouraging for future studies. The company continues to maintain a strong safety profile and financial stability. However, increased expenses and a higher net loss pose challenges. The sentiment overall leans slightly positive given the promising trial results and financial runway.Read More>---
CGTX Stock 12 Month Forecast
Average Price Target
$5.50
▲(772.88% Upside)
Technical Analysis
Best Analysts Covering CGTX
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-35.16%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -35.16% per trade.
---